Tetrapeptides — four-amino-acid sequences — have re-emerged in 2026 as drug-like scaffolds across multiple indications, leveraging their small size, synthetic tractability, and target specificity. The class straddles the gap between conventional peptide therapeutics (typically 10-50 amino acids) and small-molecule drugs, often with better tissue penetration and lower immunogenicity than longer peptides.
Leading 2026 candidates: Aivocode's CAQK (Cys-Ala-Gln-Lys) is in IND-enabling work for acute traumatic brain injury, building on a December 2025 EMBO Molecular Medicine paper showing neuroprotective activity in rodent models through brain extracellular matrix targeting. A Journal of Peptide Science paper from May 2026 reported WDGL (Trp-Asp-Gly-Leu) — a marine-derived tetrapeptide from Ulva prolifera — that activates the Keap1-Nrf2 antioxidant pathway. GHK-Cu (Gly-His-Lys-Cu, technically a tripeptide-copper complex but commonly grouped with short-peptide drugs) is the dominant cosmetic and longevity-peptide of 2026 with the fastest-growing search-term traction in the category.
Stories here cover tetrapeptide drug-discovery announcements, mechanism papers, and clinical milestones. See #caqk, #ghk-cu, and #cyclic-peptide for adjacent threads.
A Journal of Peptide Science paper reported a novel four-amino-acid peptide WDGL (Trp-Asp-Gly-Leu) derived from Ulva prolifera — the green algae species responsible for major coastal blooms in East Asia. The peptide was identified through virtual screening of marine-derived peptide libraries, binds Keap1 at key residues, and activates the Nrf2 antioxidant pathway in cellular oxidative-stress models. In vitro pharmacokinetic profiling showed favorable properties for further development. The mechanistic rationale: Keap1-Nrf2 activation drives expression of antioxidant response element (ARE)-regulated genes including superoxide dismutase, catalase, and glutathione peroxidase, reducing reactive oxygen species (ROS) and oxidative damage. The WDGL work joins a small but growing literature on tetrapeptides as drug-like scaffolds — Aivocode's CAQK brain-injury tetrapeptide being the other May 2026 example. Marine-derived AMP and bioactive peptide discovery remains an underexplored chemistry frontier.
Aivocode is preparing first-in-human Phase 1 dosing for its CAQK tetrapeptide candidate in acute traumatic brain injury, building on the December 2025 EMBO Molecular Medicine paper that established the neuroprotective mechanism in rodent models. CAQK is a four-amino-acid peptide (Cys-Ala-Gln-Lys) that homes specifically to brain extracellular matrix exposed by tissue damage, enabling targeted delivery of therapeutic payloads to injured but not healthy brain regions. The preclinical data showed reduced lesion volume and improved functional recovery in mouse and rat TBI models when CAQK was conjugated to neuroprotective small molecules. The Phase 1 program — IND-enabling work ongoing — would represent one of the few peptide-based TBI candidates entering clinical testing, an indication with no FDA-approved neuroprotective therapies.
An IQAC-CSIC, UC Davis, and Aivocode collaboration published in EMBO Molecular Medicine demonstrates that the four-amino-acid peptide CAQK, given intravenously after acute traumatic brain injury, homes specifically to a protein overexpressed in injured brain tissue and reduces lesion size, inflammation, and cell death. In mouse and pig TBI models, CAQK-treated animals showed lower expression of inflammatory markers and improved memory and behavioral test outcomes versus untreated controls, with no overt toxicity. Aivocode — a Sanford Burnham Prebys spin-out — has signaled it will seek FDA authorization to begin Phase 1 human trials. The work targets a market with no approved drug for stopping secondary TBI damage; Spain alone records about 100,000 TBIs annually.